Introduction
CPT-11 (irinotecan) is a derivative of camptothecin which acts as a DNA topoisomerase 1 inhibitor. It is arguably one of the most significant anticancer agents to have appeared in recent years, and is under development for the treatment of colorectal cancer and other solid tumours.
In preclinical investigations, CPT-11 was active against colorectal, non-small-cell lung, ovarian and breast tumour colony-forming units [1] . This broad spectrum of anticancer activity was confirmed in mice transplanted with human tumour xenografts, including colon, mammary, gastric and squamous cell lung carcinomas [2] . Anticancer activity against multidrug-resistant human tumour cell lines has also been demonstrated [3] . Furthermore, CPT-11 has shown a lack of complete cross-resistance with another inhibitor of DNA topoisomerase 1, topotecan [4] . These observations highlight the unique mechanism of action of CPT-11 and are suggestive of a potential clinical advantage in the treatment of patients with drug-resistant tumours.
In vivo, CPT-11 is converted into an active metabolite, SN-38, which has demonstrated in vitro antitumour activity > 100-fold greater than that of the parent compound [5] . SN-38 was the most potent camptothecin derivative in a human colon carcinoma cell model [6] .
Pharmacokinetic analyses from phase I studies revealed that the elimination half-lives of CPT-11 and SN-38 ranged from 9.3 to 14.2 and 7.7 to 13.8 hours, respectively [7] [8] [9] . These values are considerably longer than the half-life of approximately 3 hours reported for topotecan [10, 11] . A long elimination half-life may be an important factor in the antitumour activity of CPT-11. Inhibitors of DNA topoisomerase 1 appeared to be extremely cycle-phase specific [12] . Therefore, increased exposure time of tumour cells to the drug by virtue of its long elimination half-life should result in prolonged inhibition of DNA topoisomerase 1 and, therefore, greater clinical efficacy.
In vivo preclinical studies investigating the schedule dependency of CPT-11 on its antitumour activity have produced contradictory results. Bissery et al. [13] concluded that CPT-11 was not markedly schedule dependent, while other investigators have suggested that more potent topoisomerase 1 inhibition may be achieved by using a protracted dosage schedule [4] or repeated administration [14] .
Only 1 phase I study [15, 16] , involving a small number of Japanese patients (n -21), had been published prior to commencement of European phase I studies. The conclusion of the haematological dose-limiting toxicity (DLT) and of a maximum tolerated dose (MID) of 250 mg/m 2 were not supported by a mild reported haematological toxicity and the MTD with this schedule had to be reassessed. The European phase I studies were started in 1990 to select an appropriate dosage schedule for CPT-11. The schedules evaluated in these studies were a 30 minutes i.v. infusion given every 3 weeks [7] , daily for 3 consecutive days every 3 weeks [8] , and weekly for 3 out of 4 weeks [9] . Because CPT-11 has a long terminal half-life and there was no evidence of schedule dependency in preclinical studies, a continuous infusion administration schedule was not investigated. The purpose of this review is to provide a rationale for the selection of an appropriate CPT-11 dosage schedule for use in phase II studies of the drug in Europe, by reviewing the results of the 3 European studies of CPT-11 [7] [8] [9] . Two of the studies continued to enrol patients in further feasibility phases following the initial dose-escalation phases reported in the original publications [7, 9] ; results from the total populations are presented here.
Study design
The same study design with standardised patient inclusion criteria and methods were used in all 3 of the European studies. The 3 investigated schedules were decided on and performed concomitantly by a board of investigators who met regularly and exchanged information. Eventually, they treated some patients with another schedule to improve their knowledge of the safety according to the protocol. The protocols were approved by an ethical committee and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Patients were aged between 18 and 75 years, had a histologically confirmed malignant solid tumour refractory to conventional therapy or for which no curative therapy existed, had a life expectancy of >3 months, an ECOG performance status between 0 and 2 and had not been treated with chemotherapy or radiotherapy in the 4-week period prior to study entry. Written informed consent was obtained from all patients.
The 3 open-label studies evaluated the following schedules for CPT-11 administered by a 30 minutes i.v. infusion: once every 3 weeks [7] , once daily for 3 consecutive days every 3 weeks [8] and once weekly every 3 out of 4 weeks [9] .
The studies were dose-escalating and dose-finding. Doses were escalated to pre-determined levels in successive cohorts of patients. At least 3 patients were to be included at each dose level. If no grade 3 or 4 toxicity was observed in these 3 patients, further escalation was performed at the next dose level. If at least 1 patient experienced grade 3 or 4 toxicity in the first cycle, at least 3 additional patients were to be enrolled at the same dose level.
The MTD in the European studies was defined as the dose level at which >50% of patients developed WHO grade 3 or 4 of the same toxicity with the exception of emesis and alopecia. The dose level immediately below the MTD was the recommended dose for phase II studies.
Studies: results
A total of 235 patients with refractory malignant solid tumours were enrolled in the 3 European phase I studies and doses ranging from 100 to 750 mg/m 2 /3 weeks were administered. The patient characteristics for the 3 study populations were broadly comparable, with the exception that one study [7] enrolled a higher ratio of males to females (62%/38%, vs. 48%/52% and 49%/ 51%), with a slightly higher performance status (ECOG 0-1: 98%) than the other 2 studies (0-1: 85%, 76%) [8, 9] . The median age of patients in the 3 studies ranged from 51 to 56 years. Colorectal cancer was the most frequent tumour type, occurring in 25%-41% of patients enrolled, and 86%-93% of patients had received prior chemotherapy. The number of patients assigned to each dose level for each of the 3 studies is summarised in Table 1 .
Safety
Neutropenia and diarrhoea were the major dose-limiting toxicities with all of the treatment schedules and their incidences at different dose levels are shown in Table 2 .
Two types of diarrhoea, early and late onset, were differentiated using the once every 3 weeks schedule [7] . In fact, this was the first time the acute cholinergiclike syndrome had been described. A dissociation between early and delayed diarrhoea was also demonstrated using the 3 days every 3 weeks schedule [8] . However, these 2 variants of this toxicity could not be differentiated in the weekly schedule of administration, probably because of temporal overlap in their occurrence [9] . Early onset diarrhoea, starting during or immediately after CPT-11 infusion, was of short duration and part of an acute cholinergic-like syndrome. Other symptoms of this syndrome included abdominal cramps, sweating and less frequently, salivation, visual disturbances and lachrymation. These symptoms were reversible using atropine sulphate. Indeed, the cholinergic properties of CPT-11 could be supported by the presence of a piperidino-piperidinyl side-chain on the CPT-11 molecule [17] .
Delayed onset diarrhoea, which followed a more severe and prolonged course than that associated with the early cholinergic syndrome, was both dose-and schedule-dependent. Its occurrence was unpredictable, varying from one cycle to the next, and occurring between 2 and 14 days after administration of CPT-11. The use of a planned high-dose loperamide regimen with the once every 3 weeks schedule was effective in [9] (data on file, Rhone-Poulenc Rorer). d In this study [7] patients enrolled at dose levels >375 mg/m 2 received high-dose loperamide (2 mg every 2 hours) at the first sign of delayed diarrhoea.
reducing the severity of delayed diarrhoea and masked the symptoms at higher doses of CPT-11 [7] . In this study, delayed onset diarrhoea became dose-limiting at the 350 mg/m 2 dose level. Therefore, in patients enrolled at higher dose levels (>400 mg/m 2 ) loperamide was initiated at the first diarrhoeal episode occurring >8 hours after the end of CPT-11 infusion, at a dosage of 2 mg every 2 hours for up to 3 days or until 12 hours after the last episode of diarrhoea. This approach was effective in controlling delayed diarrhoea and dose escalation could be continued until neutropenia became dose-limiting at 750 mg/m 2 [7] . In contrast, in the other 2 studies [8, 9] , ad hoc use of various antidiarrhoeal agents, including low-dose loperamide, diphenoxylate, atropine, dismectide, codeine and octreotide, was ineffective at controlling the symptoms of delayed diarrhoea. In both of these studies, the combination of delayed diarrhoea and neutropenia was dose-limiting at 115 mg/m 2 /dose.
Although the severity of neutropenia varied considerably between patients, neutropenia was both doseand schedule-dependent (Table 3 ). The neutrophil nadir occurred between days 21 and 25 with the weekly schedule [9] and between days 6 and 9 with once every 3 weeks schedule [7] .
Significantly, the incidence and severity of the primary dose-limiting toxicities were lowest with the once every 3 weeks regimen when CPT-11 was given at the recommended dose for each of the 3 administration schedules assessed (Table 4) . This was reflected in the Table 2 . Diarrhoea and neutropenia at each dose level in the three European phase I studies of CPT-11 [7] [8] [9] . 1 Grade 3 and 4 events were not reported separately in this publication [8] . b The incidence of hospitalisations was not reported in this publication [8] . c In this study [7] patients enrolled at dose levels >350 mg/m 2 received high-dose loperamide (2 mg every 2 hours) at the first sign of delayed diarrhoea, continuing until 12 hours after the last episode of diarrhoea or for up of 3 days. n -number of patients treated and assessable for toxicity.
actual dose intensity achieved with this regimen, which was highest both in absolute terms (112 mg/m 2 /week for the once every 3 weeks regimen vs. 70-87 mg/m 2 / week for the other regimens), and relative to the planned dose intensity (96% vs. 81%-93%). Similarly, the once every 3 weeks schedule was clearly better tolerated than the 2 other regimens in an overall analysis of specific adverse events for comparative dose levels (Table 5) . It was therefore clear that the once every 3 week schedule was better tolerated at higher CPT-11 doses and that it should be selected for phase II trials on an out-patient basis. However, by the end of 1991, the actual criteria of MTD were not yet reached, although delayed diarrhoea was obviously identified as the DLT with the once every 3 weeks schedule at a dose of 350 mg/m 2 ( Table 4) . At the same time, the MTD of the other 2 schedules was well defined (Table 4) .
Thus, since 350 mg/m 2 every 3 weeks was associated with the highest dose intensity and the least toxicity, it was the more suitable schedule on an out-patient basis for phase II studies. These studies were initiated in early 1992 using the 350 mg/m 2 once every 3 weeks schedule.
Concomitantly, dose-escalation was continued in the phase I study with this schedule with the support of high-dose loperamide. Doses of CPT-11 above 350 mg/m 2 were referred to as high doses and using this regimen doses up to 750 mg/m 2 could be reached.
Efficacy
Although clinical efficacy was not a primary endpoint of these phase I studies, a number of observations of clinical response were made. Indeed, an equivalent number of responses were observed with all schedules at comparable dose levels, and a dose-effect relationship was evident with high doses of CPT-11. With the once every 3 weeks administration schedule, objective responses were more often observed at high CPT-11 doses. Particularly noteworthy were 6 partial responses obtained with CPT-11 doses >350 mg/m 2 , in 12 patients with colorectal cancer refractory to 5-fluorouracil [7] . This result could be explained by the better physical condition of the patients, enabling them to receive higher dose of CPT-11 (>350 mg/m 2 ) and making them more likely to respond to CPT-11. However, this has yet to be confirmed.
Discussion
On the basis of its novel mechanism of action, potent and the wide spectrum of activity in in vitro and in vivo carcinoma models, and encouraging results in an early Japanese clinical trial, phase I studies of CPT-11 were instituted in Europe. To date, European phase I studies have provided the most extensive and important data concerning the choice of administration schedule for CPT-11; 235 patients were included in European and 147 patients in US and Japanese phase I trials. The rationale for selecting the once every 3 weeks schedule from the European data collected by a common board of investigators was: lower toxicity at a higher dose intensity over multiple cycles (> 3) and convenience in an out-patient setting.
The actual delivered dose intensity of the once every 3 weeks schedule over multiple (>3) cycles at the recommended dose of 350 mg/m 2 (112 mg/m 2 /week) is higher than that of the weekly schedule selected for assessment at phase II in the US and Japan (100 mg/ m 2 /week). Similarly, this dose is higher than those achieved in non-European phase I studies. These include MTDs of 250 mg/m 2 every 4 weeks in a Japanese study [15] and 240 mg/m 2 every 3 weeks in a US study [18] .
Although the use of high-dose loperamide has downstaged the main limiting toxicity, discrepancies between European results and those of phase I studies conducted in Japan and the US could be explained by differing definitions of MTD, since there is no worldwide standard definition for MTD. In contrast to the European definition of MTD (the dose level at which >50% of patients developed WHO grade 3 or 4 of the same toxicity with the exception of emesis and alopecia), the Japanese investigators previously defined MTD as the dose level above which severe life-threatening toxic effects occur. The US definition of MTD is also different from that used in European studies. It was defined as the highest dose level at which 1 out of 6 patients experienced either absolute neutrophil count <500/mm 3 for >5 days or with fever; platelet count <25 000/mm 3 ; prolonged recovery delaying re-treatment for > 1 week; or any grade 3 to 4 toxicity (including emesis). If ^ 2 of 6 patients experienced 1 of these toxicities the dose level was considered over the MTD. To reach the MTD by the European definition it was necessary to observe several severe adverse events of the same type, for example, 3 episodes of grade 3/4 diarrhoea. This was considerably more difficult than observing several severe adverse events regardless of the type, for example, 1 episode each of nausea and vomiting, diarrhoea and neutropenia, as was necessary for the US and Japanese definitions of MTD. Therefore, this may be the reason why the MTD was higher in the European studies than in the US and Japanese studies. Attempts to select a universally acceptable dosage schedule for CPT-11 are further complicated by the nature of the DLTs and their assessment. In particular, diarrhoea is an unpredictable side effect and can be influenced by factors other than drug therapy. Furthermore, assessment of diarrhoea and its severity is subjective and may vary between studies. Nevertheless, it is important to note that among the 3 European studies reviewed above, at dosages <375 mg/m 2 /3 weeks, the incidence of delayed diarrhoea (including severe, grade 3/4), was lowest in the study by Abigerges et al. [7] , in which CPT-11 was administered once every 3 weeks.
Although there is recent data on the schedule dependency of CPT-11, the preclinical data suggest that a protracted schedule may be more active in terms of topoisomerase 1 inhibition [4] . These data suggest that future research may be directed at evaluation of the antitumour efficacy of protracted administration of CPT-11 in the clinical setting.
The aetiology of the delayed diarrhoea associated with CPT-11 treatment is not yet fully understood, but is thought to be related to enterohepatic circulation and resulting high intestinal concentrations of SN-38, an active metabolite of CPT-11 [19] ; this metabolite is though to have a direct toxic effect of SN-38 on gastrointestinal cells. The use of a high-dose loperamide regimen (2 mg every 2 hours), initiated promptly in response to the first symptoms of delayed diarrhoea, was effective in controlling the symptoms of delayed diarrhoea associated with high-dose CPT-11 (400-750 mg/m 2 ) [7] . In a feasibility study of CPT-11 at dose levels of 500 mg/m 2 , Tiorfan® (acetorphan, an enkephalinase inhibitor with antisecretory properties) was used as an alternative to high-dose loperamide as a preventive treatment of CPT-11 induced late diarrhoea and achieved excellent control [20] . These findings may have important consequences for dose-escalation, since initial data indicating a possible dose-effect relationship with high-dose CPT-11 indicate the potential for greater anticancer activity with the use of higher doses of CPT-11. A dosage of 500 mg/m 2 once every 3 weeks might be well tolerated with appropriate control of diarrhoea. In contrast, early onset diarrhoea may be associated with cholinergjc stimulation, an entirely different mechanism [21] , and appears to be manageable with atropine treatment. Clarification of the aetiology of these toxicities will assist in the development of more effective premedication regimens to limit or prevent early and delayed onset diarrhoea.
Conclusion
Based on the results of European phase I studies the CPT-11 administration schedule selected for evaluation in phase II trials was a single i.v. infusion administered every 3 weeks at a recommended starting dosage of 350 mg/m 2 . The highest dose intensity with the least toxicity and ease of use in an out-patient setting were the main criteria for the selection of this dosage schedule. However, it is possible that other schedules may be superior. The use of a higher dose, 500 mg/m 2 , with improved control of diarrhoea and the use of other schedules of administration (e.g., protracted infusion) deserve further evaluation.
Additional studies should be conducted at phase II level and beyond to assess the possibility of further CPT-11 dose escalation with the concomitant use of supportive treatments, such as growth factors and antidiarrhoeal agents, to overcome or improve the primary dose-limiting toxicities of this promising new anticancer agent
